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We read with interest the article from Shanin et al.
about the Fungal Infection Risk Evaluation (FIRE) study
[1] aiming to ‘describe the incidence of IFD in UK crit-
ical care units and to develop and validate a clinical risk
prediction tool to identify non-neutropenic, critically ill
adult patients at risk of IFD’. The investigators should be
congratulated for the way they collected a huge amount
of data from 96 adult intensive care units (ICUs), man-
aged the FIRE database, and developed and validated the
risk model. However, they stated that the prediction
model would help to identify patients who may benefit
from antifungal prophylaxis and that a number of ran-
domized controlled trials (RCTs) demonstrated a benefi-
cial effect of antifungal prophylaxis and/or empiric
treatment in terms of incidence of invasive fungal disease
(IFD) and mortality. This statement is not supported by
available evidence from RCTs. A recent Cochrane System-
atic Review including 22 RCTs evaluating prophylaxis,
pre-emptive, and empiric antifungal treatment with any
antifungal drugs in 2761 non-neutropenic critically ill pa-
tients showed no significant effect on mortality (risk ratio
(RR) 0.93, 95 % confidence interval (CI) 0.79 to 1.09)
and a significant reduction in the risk of invasive fungal
infection (IFI) (RR 0.57, 95 % CI 0.39 to 0.83) [2, 3]. In
the subgroup analysis for type of intervention, antifun-
gal prophylaxis was not associated with a significant
mortality reduction but with a significant reduction of
IFI [4]. This systematic review was the update of the
one cited in the manuscript and published in 2006
including 12 RCT and 1606 patients.
Resistance to antifungals has become an increasingly
burning clinical challenge. It concerns not only azoles
but also the relatively new echinocandins [5]. Notably,
the increasing use of antifungal drugs is linked to the de-
velopment of resistance, whereas infections by resistant
Candida spp. are linked to worse outcome [5]. How
should predictive tools be used to identify patients at
risk of IFI? What should we do after identifying a patient
at risk of IFI while waiting for microbiology results?
Maybe the answer should not be just giving antifungal
prophylaxis as we did in the past. A more complex
approach including the use of surrogate markers (e.g.,
beta-D-glucan), early use of other diagnostic test (e.g.,
multiplex polymerase chain reaction test, MALDI-
TOF), source control, daily evaluation of risk factors,
and, finally, in some cases the wise use of antifungal
drugs according to local epidemiology may be answer.
To simplify, antifungal stewardship is what we should
implement to balance risk and benefit.
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